Advances in the study of EVI1 in acute myeloid leukemia

Abstract

Wu Shiwei, Pei Kangjia, Zhang Dongxing, Qin Zhanyu, Guo Shuxia. Advances in the study of EVI1 in acute myeloid leukemia[J]. Journal of International Oncology, 2024, 51(7): 474-477.

References26

[1]	陈晓奉, 王蒙, 李忠玉, 等. Venetoclax联合化疗治疗复发/难治性急性髓系白血病的临床研究[J].中国全科医学,2022,25(8): 957-962. DOI:10.12114/j.issn.1007-9572.2022.02.005.
[2]	Lux S, Milsom MD. EVI1-mediated programming of normal and malignant hematopoiesis[J].Hemasphere,2023,7(10): e959. DOI:10.1097/HS9.0000000000000959. pmid:37810550
[3]	Nabil R, Abdellateif MS, Gamal H, et al. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia[J].Leuk Res,2023,126: 107019. DOI:10.1016/j.leukres.2023.107019.
[4]	Liang BY, Wang J. EVI1 in leukemia and solid tumors[J].Cancers (Basel),2020,12(9): 2667. DOI:10.3390/cancers12092667.
[5]	Schmoellerl J, Barbosa IAM, Minnich M, et al. EVI1 drives leukemogenesis through aberrant ERG activation[J].Blood,2023,141(5): 453-466. DOI:10.1182/blood.2022016592.
[6]	Paredes R, Schneider M, Pearson S, et al. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle[J].Mol Biol Rep,2020,47(10): 8293-8300. DOI:10.1007/s11033-020-05829-1.
[7]	Nagai K, Niihori T, Muto A, et al. Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice[J].Blood Adv,2023,7(18): 5409-5420. DOI:10.1182/bloodadvances.2022008462.
[8]	Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression[J].Cancer Cell,2014,25(4): 415-427. DOI:10.1016/j.ccr.2014.02.008. pmid:24703906
[9]	Kreider BL, Orkin SH, Ihle JN. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene[J].Proc Natl Acad Sci U S A,1993,90(14): 6454-6458. DOI:10.1073/pnas.90.14.6454.
[10]	Morishita K, Parganas E, Matsugi T, et al. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor[J].Mol Cell Biol,1992,12(1): 183-189. DOI:10.1128/mcb.12.1.183-189.1992. pmid:1370341
[11]	Yamaoka A, Suzuki M, Katayama SR, et al. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis[J].Blood Adv,2020,4(8): 1722-1736. DOI:10.1182/bloodadvances.2019000978. pmid:32330245
[12]	Mittal N, Li LP, Sheng Y, et al. A critical role of epigenetic inactivation of miR-9 in EVI1^highpediatric AML[J].Mol Cancer,2019,18(1): 30. DOI:10.1186/s12943-019-0952-z. pmid:30813931
[13]	Lang WJ, Han XF, Cai JY, et al. Ectopic viral integration site-1 oncogene promotes NRAS pathway through epigenetic silencing of microRNA-124 in acute myeloid leukemia[J].Cell Signal,2022,99: 110402. DOI:10.1016/j.cellsig.2022.110402.
[14]	Jiang M, Zou XQ, Huang WH. Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGFβ/EMT signaling pathway[J].Oncol Lett,2018,16(2): 2701-2708. DOI:10.3892/ol.2018.8890. pmid:30013666
[15]	Kotaki R, Higuchi H, Ogiya D, et al. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia[J].Int J Hematol,2017,106(6): 811-819. DOI:10.1007/s12185-017-2314-1. pmid:28831750
[16]	Masamoto Y, Chiba A, Mizuno H, et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment[J].Blood Adv,2023,7(8): 1577-1593. DOI:10.1182/bloodadvances.2022008018.
[17]	Ayoub E, Wilson MP, McGrath KE, et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription[J].Nat Commun,2018,9(1): 4239. DOI:10.1038/s41467-018-06208-y. pmid:30315161
[18]	Qin YZ, Zhao T, Zhu HH, et al. High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy[J].Med Sci Monit,2018,24: 758-767. DOI:10.12659/msm.905903.
[19]	Zheng Y, Huang Y, Le S, et al. High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia[J].Front Oncol,2021: 712747. DOI:10.3389/fonc.2021.712747.
[20]	Kiehlmeier S, Rafiee MR, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia[J].Leukemia,2021,35(11): 3127-3138. DOI:10.1038/s41375-021-01235-z. pmid:33911178
[21]	Yamamoto H, Lu J, Oba GYY, et al. MiR-133 regulates Evi1 expression in AML cells as a potential therapeutic target[J].Sci Rep,2016,6(1): 19204. DOI:10.1038/srep19204.
[22]	Paubelle E, Plesa A, Hayette S, et al. Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1[J].Oncol Ther,2019,7(2): 121-130. DOI:10.1007/s40487-019-0095-9.
[23]	Nguyen CH, Bauer K, Hackl H, et al. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia[J].Cell Death Dis,2019,10(12): 944. DOI:10.1038/s41419-019-2172-2. pmid:31822659
[24]	Nguyen CH, Grandits AM, Vassiliou GS, et al. Evi1 counteracts anti-leukemic and stem cell inhibitory effects of all-trans retinoic acid on Flt3-ITD/Npm1c-driven acute myeloid leukemia cells[J].Biomedicines,2020,8(10): 385. DOI:10.3390/biomedicines8100385.
[25]	Saito Y, Kaneda K, Suekane A, et al. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56[J].Leukemia,2013,27(8): 1637-1649. DOI:10.1038/leu.2013.75. pmid:23478665
[26]	Saha HR, Kaneda-Nakashima K, Shimosaki S, et al. Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression[J].Sci Rep,2018,8(1): 13741. DOI:10.1038/s41598-018-32205-8. pmid:30214063

Advances in the study of EVI1 in acute myeloid leukemia

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References26

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Yu Cedric, Ren Lei, Lu Xiaoguang.Debates and reflection on modern proton radiotherapy and photon radiotherapy[J]. Journal of International Oncology, 2024, 51(7): 411-416.
[2]	Kong Lin, Lu Jiade.Breakthroughs and challenges： clinical application and progress of proton and heavy ion radiotherapy for malignant tumors[J]. Journal of International Oncology, 2024, 51(7): 417-423.
[3]	Saber Amin, Chi Lin.Trends of the use of proton beam radiation therapy in patients with central nervous system tumors： analysis of National Cancer Database (2004-2021）[J]. Journal of International Oncology, 2024, 51(7): 424-431.
[4]	Zhao Biao, Pu Qin, Yuan Meifang, Ma Lishuang, Li Han, Yang Yi, Sun Chaoxi.Dosimetric study of intensity-modulated radiotherapy and volumetric intensity modulated arc therapy based on the inner edge tangent field for radiotherapy after breast-conserving surgery of left-sided breast cancer[J]. Journal of International Oncology, 2024, 51(7): 441-447.
[5]	Yu Hongxin, Bai Yan, Gong Yuan, Wang Jianzhuang, Fan Zhigang.Risk factors and predictive model construction of brain metastases in patients with limited-stage SCLC undergoing preventive brain radiotherapy after remission[J]. Journal of International Oncology, 2024, 51(7): 453-457.
[6]	Du Qilian, Hu Qinyong.Tumor-infiltrating immune cells from a single-cell perspective[J]. Journal of International Oncology, 2024, 51(7): 458-463.
[7]	Liu Jing, Zhang Jun.Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma[J]. Journal of International Oncology, 2024, 51(7): 464-467.
[8]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[9]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[10]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[11]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[12]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[13]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[14]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[15]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.